Including Pharmaceuticals in Bundled Payments Gerard F. AndersonAndrew YorkJoshua L. Choe Commentary 08 July 2022 Pages: 625 - 628
Using Economics to Impact Local Obesity Policy: Introducing the UK Centre for Economics of Obesity (CEO) Emma FrewNafsika AfentouIrina Pokhilenko Current Opinion Open access 20 June 2022 Pages: 629 - 635
Centralised Pharmaceutical Procurement: Learnings from Six European Countries Sabine VoglerEveli BauerKatharina Habimana Practical Application 06 May 2022 Pages: 637 - 650
Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy Chris SampsonBernarda ZamoraAdrian Towse Review Article Open access 07 June 2022 Pages: 651 - 667
UroLift for Treating Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A NICE Medical Technology Guidance Update Laura KnightMegan DaleRhys Morris Review Article Open access 18 July 2022 Pages: 669 - 680
An Economic Evaluation of Government-Funded COVID-19 Testing in Australia Jonathan KarnonHossein Haji Ali AfzaliBillie Bonevski Original Research Article Open access 02 August 2022 Pages: 681 - 691
Information Asymmetry in Hospitals: Evidence of the Lack of Cost Awareness in Clinicians Jeremy FabesTuba Saygın AvşarThe Health Economics Survey Group Original Research Article 24 May 2022 Pages: 693 - 706
Does the Choice of Health Metric, DALY or QALY, Influence Conclusions of Health Economic Evaluation? A Case Study of Rotavirus Vaccine in Burundi Fulgence NiyibitegekaMontarat ThavorncharoensapSitaporn Youngkong Original Research Article 26 April 2022 Pages: 707 - 716
Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive Cancers Renée E. MichelsCarlos H. ArteagaMarieke Krol Original Research Article Open access 18 July 2022 Pages: 717 - 729
ENTIMOS: A Discrete Event Simulation Model for Maximising Efficiency of Infusion Suites in Centres Treating Multiple Sclerosis Patients Kristyna LacinovaPraveen ThokalaNicholas Adlard Original Research Article Open access 19 May 2022 Pages: 731 - 742
Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model Jia LiuXiaoning HeJing Wu Original Research Article 28 April 2022 Pages: 743 - 755
Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland Daniel Tobias MichaeliMackenzie MillsPanos Kanavos Original Research Article Open access 11 July 2022 Pages: 757 - 768
Cost-Effectiveness and Budget Impact Analysis of Implementing a 'Soft Opt-Out' System for Kidney Donation in Australia Sameera SenanayakeHelen HealySanjeewa Kularatna Original Research Article Open access 18 July 2022 Pages: 769 - 779
Correction to: Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations Don HusereauMichael DrummondSophie Staniszewska Correction Open access 15 July 2022 Pages: 781 - 782
